New treatment approach for primary central nervous system lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates a novel treatment regimen combining rituximab, methotrexate, and thiotepa for induction therapy, followed by etoposide and cytarabine for consolidation in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The study aims to improve the overall response rate and prolong disease-free survival, particularly in younger patients. By assessing the safety, efficacy, and tolerability of this regimen, the trial seeks to optimize frontline therapy for PCNSL and address the high relapse rates associated with current treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≤ 60 years, male or female
* Histologically and immunohistochemically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) without prior treatment
* No evidence of systemic lymphatic or hematopoietic involvement or other systemic disease, based on thorough physical examination and imaging/laboratory tests
* Diagnosis meets criteria for Primary Central Nervous System Lymphoma (PCNSL)
* Written informed consent obtained from the patient or their legal guardian
* Voluntary agreement to participate in the study

Exclusion Criteria:

* Presence of another active malignancy
* Known history of HIV infection or diagnosis of acquired immunodeficiency syndrome (AIDS)
* Known allergy to any of the investigational drugs or their excipients
* Any condition that, in the opinion of the investigator, may lead to early study termination, including but not limited to:
* Severe comorbidities
* Significant laboratory abnormalities
* Serious social or family circumstances affecting safety or compliance

Where it's running

• Facility Name: The First Hospital of Jilin University
  Changchun, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib for newly diagnosed primary or secondary CNS lymphoma

  This trial will test whether combining a PD‑1 blocker with rituximab, high‑dose methotrexate, and orelabrutinib helps people with newly diagnosed primary or secondary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07410520

• R-PMDT Regimen for Newly Diagnosed PCNSL

  This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07604987

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Selinexor with high-dose methotrexate, rituximab, and low-dose whole-brain radiotherapy for newly diagnosed CNS lymphoma patients who can't have transplant

  We will test whether adding oral selinexor to high-dose methotrexate and rituximab followed by low-dose whole-brain radiotherapy can help people with newly diagnosed central nervous system lymphoma who are not candidates for stem cell transplant.

  Recruiting Phase 2 Second Affiliated Hospital of Soochow University · Suzhou · NCT07002099

• ZR-MTX combo for newly diagnosed primary intraocular lymphoma

  This trial tests a Rituximab, Zanubrutinib, and methotrexate cocktail plus intravitreal methotrexate in people newly diagnosed with primary intraocular lymphoma to see if it can extend the time before the disease progresses.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06973811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.